Rosemary A. Crane

Crane retired in 2014 from MELA Sciences Inc, where she served as president and CEO. Previously she was a partner and head of Commercialization at Appletree Partners, and served as CEO and president of Epocrates Inc.  She also held several senior executive positions at the Johnson & Johnson Group of Companies as well as Bristol-Myers Squibb Co. She is on the boards of Edge Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S.

  • 2018 Second Quarter

Added to: Catalent Inc. - Somerset, NJ

Catalent provides advanced delivery technologies for drugs and consumer health products. Revenues are $4 billion.